Review on CTDSPL, with data on DNA/RNA, on the protein encoded and where the gene is implicated. 
DNA/RNA

Description
Located in the short (p) arm of chromosome 3, the length of the CTDSPL gene is about 122.5 kb, contains 8 exons and is arranged in a telomere to centromere orientation.
Transcription
The full length transcript of CTDSLP is 4459 bp (Ensembl, Transcript ID ENST00000443503). A total of 8 transcripts can be generated, out of which 5 are protein coding, 1 undergoes nonsense mediated decay, while the rest 2 do not code for a protein product. However, two splice variants of CTDSPL, the smaller CTDSPL A (lacking exon 3, therefore short of 33 bp, 11 amino acids) and the full length CTDSPL B were identified by Kashuba et al., 2004. Interesting observation: The transcription start site for CTDSPL A and CTDSPL B are different (from ensemble.org). While the larger B form has a shorter 5'UTR, the smaller A form has a larger 5'UTR, although their translation start sites remain common. Difference in the size of the 5'UTR may account for differential splicing between the isoforms.
Pseudogene
None reported.
Protein
Description
The full length CTDSPL protein (CTDSPL B) is 276 amino acids in length, with a molecular weight of 31 kD. The smaller protein, CTDSPL A is 265 amino acids in length (amino acids 79-89 missing) and 29.9 kD in weight. Amino acids 102-260 contain the FCP1 homology domain, which contains an essential protein serine phosphatase that dephosphorylates the C-terminal domain (CTD) of RNA polymerase II.
Localisation
Both nuclear and cytoplasmic (Maiti et al., 2012; Sarkar et al., 2013) . (Safran et al., 2003) .
Function
-CTDSPL is a serine phosphatase which regulates cell growth and differentiation. It dephosphorylates RB at serine 807/ 811 (hence called RB1 serine phosphatase from human chromosome 3), thereby increasing RB-E2F interaction and halting the cell cycle at G1/S boundary ). -It also inactivates RNA polymerase-II by preferential dephosphorylation of 'Ser-5' within the tandem 7 residues repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit, thus controlling the transcription machinery (hence called carboxy-terminal domain, RNA polymerase II, polypeptide A small phosphatase-like) (Yeo et al., 2003) .
-Studies also suggest that CTDSPL/RBSP3 might function as a transcriptional co-repressor, inhibiting transcription of neuronal genes in non-neuronal cells (Yeo et al., 2005) , and may also act as a phosphatase of Smad1, Smad2/Smad3 and Snail (Wu et al., 2009; Sapkota et al., 2006) .
Homology
Chimpanzee, Rhesus monkey, dog, cow, mouse, chicken, zebrafish, S.cerevisiae, K.lactis, E.gossypii, S.pombe, M.oryzae, and N.crassa show conserved RBSP3 gene (Source NCBI homologene). RBSP3 and miRNAs 1. miRNA 100 -RBSP3 is a bonafide target for miRNA 100.
-miRNA 100 binds to the 3`UTR of RBSP3 in regions conserved in humans, rats and mice. -RBSP3 expression is inversely co-related with the expression of miRNA 100 in 76.5% AML cases. 2. miRNA 26a (has-miR-26a-1) -miRNA 26a resides in the intron of RBSP3.
-It is concomitantly expressed with RBSP3 during the cell cycle. 
Mutations
Germinal
Implicated in
Cervical cancer
Note -High deletion (48%, 45% cases) and methylation (26%, 25% cases) was seen in CIN and CACX respectively (Mitra et al., 2010 ). -Reduced mRNA expression was seen in CACX (Mitra et al., 2010 ). -RBSP3B (larger, active isoform) was underexpressed in CACX (Mitra et al., 2010 ). -In HPV infected cervical cancer, high deletion (42% cases) was observed, with significant variation (p<0.05) between metastatic (64%) and non-metastatic (32%) cases (Anedchenko et al., 2007) -Altogether, copy number change was seen in 51% cases (Anedchenko et al., 2007 ). -Decreased expression was seen in 64% cases, with significant difference between metastatic (83%) and non-metastatic (52%) cases (Anedchenko et al., 2007) . -Increase in expression was also observed in some cases (Anedchenko et al., 2007) . -Altogether, change in expression was in 79% of cases (Anedchenko et al., 2007) . Prognosis RBSP3 alterations (deletion, methylation) were significantly associated with poor patient outcome and posed 4.5-13 times risk of survival (Anedchenko et al., 2007) .
Oncogenesis
Inactivation of RBSP3 was an early event in cervical carcinogenesis (Mitra et al., 2010) .
Breast cancer
Note -Study population was divided into two groups, Group A (≤40 yrs, early onset) and Group B (>40 yrs, late onset) (Sinha et al., 2008) . -High deletion (30%, 24% cases) and methylation (38%, 32% cases) were observed in Groups A and B respectively (Sinha et al., 2008) . -28.9 ± 39.1 fold reduction in expression of RBSP3 was observed in about 33 -40% of the tumors (Sinha et al., 2008 ).
-Homozygous deletion (10-18%) was observed for RBSP3 . Prognosis Patients belonging lower to age of onset (≤40 yrs) with alterations of RBSP3 had poor disease outcome (Sinha et al., 2008) . Oncogenesis Higher alterations of RBSP3 were observed in patients belonging to the lower age of onset (Group A) (Sinha et al., 2008) .
Acute lymphoid leukemia (ALL)
Note Promoter methylation was seen in RBSP3 in 24% of ALL patients.
Prostate cancer
Note GWAS study using Affymetrix 100K SNP GeneChip with GEE model showed that the SNP, rs9311171 (G/ T), located within RBSP3, had a notable GEE p value (1.8x 10 -6 ).
Oncogenesis GEE p value 1.8x 10 -6 indicates that this SNP within RBSP3 plays a role in tumor progression.
Non -small cell lung cancer (NSCLC)
Note -Reduction of expression of RBSP3 was obtained for both adenocarcinoma (AC) and squamous cell carcinoma (SCC) (Senchenko et al., 2008) . -Downregulation was both genetic and epigenetic (Senchenko et al., 2008 ). -For ACs, decrease in level of expression was in 88% cases and 70% cases of metastatic and nonmetastatic tumors respectively, whereas for SCCs, it was in 88% cases for both metastatic and nonmetastatic tumors (Senchenko et al., 2008) . -Decrease in mRNA in ACs was due to deletion (25% cases) and promoter methylation (38% cases), whereas for SCCs, it was in 30% and 80% cases for deletion and methylation respectively (Senchenko et al., 2008) . -Fold decrease in expression of RBSP3 in AC and SCC was 78% and 88% respectively, with overall 85% decrease in expression of RBSP3 in NSCLC (Senchenko et al., 2010) . Oncogenesis Deletion and methylation of promoter of RBSP3 are responsible for reduction in expression of the protein and play important roles in progression of NSCLC (Senchenko et al., 2008) . Reduction of expression of RBSP3 is required for development of lung adenocarcinomas (Senchenko et al., 2010) .
Ovarian cancer
Note Deletion/Methylation of RBSP3 were observed in 33% cases. Oncogenesis RBSP3 deletion/methylation can be used as a biomarker for ovarian cancer in combination with other studied markers.
Head and neck squamous cell carcinoma (HNSCC)
Note -Deletion of RBSP3 in dysplasia and HNSCC was in 24% and 32% cases respectively (Ghosh et al., 2010 ). -Promoter methylation was observed in 39% and 38% cases of dysplasia and HNSCC samples respectively (Ghosh et al., 2010) . -Fold reduction of mRNA in the tumors was 33.6 ± 9.4 (Ghosh et al., 2010) . -While normal tissues expressed the larger RBSP3 B form, tumors either showed no expression of RBSP3, or preferentially expressed the smaller, less active form, RBSP3 A (Ghosh et al., 2010) . Expression of RBSP3 decreases from pre-malignant to malignant lesions (Maiti et al., 2012) . Expression of RBSP3 was seen to be increased from pre-neoadjuvant chemotherapy tumors to post-therapy tumors (Sarkar et al., 2013) . Prognosis Patients with RBSP3 alterations show poor survival (Ghosh et al., 2010) . Oncogenesis Early alteration of RBSP3 takes place in head and neck cancers (Ghosh et al., 2010) . Loss of expression of RBSP3 was seen to be required for progression from malignant to invasive cancer (Maiti et al., 2012) . Regain of expression of RBSP3 in post-therapy tumors may be one of the reasons of shrinkage of tumors due to neoadjuvant chemotherapy (Sarkar et al., 2013) .
Lung, renal, breast, cervical and ovarian cancers
Note High frequencies of somatic mutations in RBSP3 in different cancers suggesting it may underlay the mutator phenotype of cancer.
